REGENXBIO, Inc. is a pharmaceutical company based in the United States, specializing in developing and commercializing gene therapy using recombinant adeno associated virus technology to treat genetic disorders. The company focuses on addressing metabolic, neurodegenerative, and retinal diseases. With a medium risk rating ESG score of 28.9, REGENXBIO is dedicated to driving sustainability and governance within the biotechnology industry.